Trauma Medical Center, Department of Orthopaedic surgery, West China Hospital, Sichuan University, Chengdu, 610041, China.
Department of Orthopedics, Orthopedic Research Institute, West China Hospital, Sichuan University, Chengdu, 610041, China.
Small. 2023 Aug;19(32):e2207231. doi: 10.1002/smll.202207231. Epub 2023 Apr 17.
Tendon stem/progenitor cells (TSPCs) therapy is a promising strategy for enhancing cell matrix and collagen synthesis, and regulating the metabolism of the tendon microenvironment during tendon injury repair. Nevertheless, the barren microenvironment and gliding shear of tendon cause insufficient nutrition supply, damage, and aggregation of injected TSPCs around tendon tissues, which severely hinders their clinical application in tendinopathy. In this study, a TSPCs delivery system is developed by encapsulating TSPCs within a DNA hydrogel (TSPCs-Gel) as the DNA hydrogel offers an excellent artificial extracellular matrix (ECM) microenvironment by providing nutrition for proliferation and protection against shear forces. This delivery method restricts TSPCs to the tendons, significantly extending their retention time. It is also found that TSPCs-Gel injections can promote the healing of rat tendinopathy in vivo, where cross-sectional area and load to failure of injured tendons in rats are significantly improved compared to the free TSPCs treatment group at 8 weeks. Furthermore, the potential healing mechanism of TSPCs-Gel is investigated by RNA-sequencing to identify a series of potential gene and signaling pathway targets for further clinical treatment strategies. These findings suggest the potential pathways of using DNA hydrogels as artificial ECMs to promote cell proliferation and protect TSPCs in TSPC therapy.
肌腱干/祖细胞(TSPCs)治疗是一种很有前途的策略,可以增强细胞基质和胶原合成,并调节肌腱损伤修复过程中的肌腱微环境代谢。然而,肌腱的贫瘠微环境和滑行剪切会导致注射的 TSPCs 围绕肌腱组织的营养供应不足、损伤和聚集,这严重阻碍了它们在肌腱病中的临床应用。在这项研究中,通过将 TSPCs 包封在 DNA 水凝胶(TSPCs-Gel)中来开发 TSPCs 输送系统,因为 DNA 水凝胶通过为增殖提供营养并抵抗剪切力来提供极好的人工细胞外基质(ECM)微环境。这种输送方法将 TSPCs 限制在肌腱内,显著延长了它们的保留时间。研究还发现,TSPCs-Gel 注射可以促进大鼠肌腱病的体内愈合,与游离 TSPCs 治疗组相比,在 8 周时,大鼠受伤肌腱的横截面积和失效负荷明显提高。此外,通过 RNA 测序研究了 TSPCs-Gel 的潜在愈合机制,以确定一系列潜在的基因和信号通路靶点,用于进一步的临床治疗策略。这些发现表明,使用 DNA 水凝胶作为人工 ECM 来促进细胞增殖和保护 TSPCs 的策略在 TSPC 治疗中具有潜在的应用途径。